GSTM1 and thalassemia: Since treatment of thalassemia with a combination of hydrophobic antioxidant, hydrophilic antioxidant, and iron chelator has not been studied, this clinical trial aimed at the evaluation of the effects of two antioxidant cocktails (each comprising a hydrophobic antioxidant, a hydrophilic antioxidant, and an iron chelator) on the iron load, oxidative stress, antioxidant status, blood coagulation potential, and anemia (especially the capability of raising hemoglobin (Hb) levels) in patients with β-thalassemia/HbE.